Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue Virus
2007

Pediatric Measles Vaccine with Dengue Antigen

Sample size: 6 publication 10 minutes Evidence: moderate

Author Information

Author(s): Brandler Samantha, Lucas-Hourani Marianne, Moris Arnaud, Frenkiel Marie-Pascale, Combredet Chantal, Février Michèle, Bedouelle Hugues, Schwartz Olivier, Desprès Philippe, Tangy Frédéric

Primary Institution: Institut Pasteur, Paris, France

Hypothesis

Can a measles vaccine expressing a dengue antigen induce long-lasting immunity against dengue virus?

Conclusion

The study found that the measles vaccine expressing a dengue antigen successfully induced durable, serotype-specific neutralizing antibodies against dengue virus in mice.

Supporting Evidence

  • The vaccine induced long-term production of dengue virus serotype-specific neutralizing antibodies in mice.
  • The presence of the ectodomain of the membrane protein was critical for the immunogenicity of the dengue antigen.
  • Immunization with the vaccine resulted in a significant increase in cytokine and chemokine secretion from dendritic cells.

Takeaway

Researchers created a new vaccine that combines measles and dengue protection, and it worked well in mice, making it a promising option for kids in areas where both diseases are common.

Methodology

The study involved immunizing genetically modified mice with a recombinant measles vaccine expressing a dengue antigen and measuring the resulting antibody responses.

Limitations

The study was conducted in a mouse model, which may not fully replicate human responses.

Participant Demographics

Genetically modified CD46-IFNAR mice, susceptible to measles virus infection.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pntd.0000096

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication